Restylane Kysse receives FDA approval

Galderma’s Restylane Kysse has been approved by the FDA for lip augmentation and the correction of upper perioral rhytids in adults aged 21 and above. 

The hyaluronic acid filler contains 3mg/mL of lidocaine hydrochloride and is part of the Restylane range, which includes Restylane Classic, Lyft, Refyne, Fynesse, Volyme, Defyne; and skin boosters Vital and Vital Light.

The FDA approval was based on a randomised, controlled, evaluator-blinded, multicentre phase 3 study involving 273 patients. 

“Restylane Kysse is a new lip filler that offers key attributes both providers and their patients desire in a lip injection – high satisfaction, consistent results, and a proven clinical-safety profile,” said Alisa Lask, general manager and vice president of the US Aesthetic Business at Galderma.

Interested in thread lifts as another option for lip augmentation?